Impact of baseline covariates on the immunogenicity of a quadrivalent (Types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine

Journal of Infectious Diseases

Volumn 196, Issue 8, 2007, Pages 1153-1162

  Giuliano, Anna R ^a   Lazcano Ponce, Eduardo ^d   Villa, Luisa ^e   Nolan, Terry ^f   Marchant, Colin ^b   Radley, David ^c   Golm, Greg ^c   McCarroll, Kathleen ^c   Yu, Jimmy ^c   Esser, Mark T ^c   Vuocolo, Scott C ^c   Barr, Eliav ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNICITY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LACTATION; MAJOR CLINICAL STUDY; MALE; PAPANICOLAOU TEST; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD; SMOKING; TREATMENT RESPONSE; VACCINATION; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODY FORMATION; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME;

EID: 35348908938     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/521679     Document Type: Article

References (31)

1. Maw RD. Treatment of anogenital warts. Dermatol Clin 1998; 16:829-34.
2. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2003. J Sch Health 2004; 74:307-24.
3. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9:571-8.
4. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
5. Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84:263-70.
6. Madeleine MM, Daling JR, Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997; 89:1516-23.
7. Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002; 49:194-209.
8. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006; 6:21-31.
9. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363:1488-9.
10. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002; 35(Suppl 2):S210-24.
11. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Efficacy and safety of a prophylactic quadrivalent human papillomavirus (types 6/11/16/18) L1 virus-like-particle vaccine against cervical, vulvar, and vaginal neoplasia and intraepithelial neoplasias and anogenital condylomata: a randomized controlled trial. N Engl J Med 2007; 356:1928-43.
12. The FUTURE II Study Group. Efficacy and safety of a prophylactic quadrivalent human papillomavirus (types 6/11/16/18) L1 virus-like-particle vaccine in the prevention of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a randomized controlled trial. N Engl J Med 2007; 356:1915-27.
13. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999; 17:2129-35.
14. Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998; 252:39-45.
15. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72:8220-9.
16. Bryan JT, Jansen KU, Lowe RS, et al. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 1997; 53:185-8.
17. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65:3328-36.
18. Brown DR, Bryan JT, Schroeder JM, et al. Neutralization of human papillomarvirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184:1183-6.
19. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
20. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477-86.
21. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
22. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45.
23. Villa LL, Ault K, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24:5571-83.
24. Siber GR, Santosham M, Reid GR, et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990; 323:1387-92.
25. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17(Suppl 9):S117-22.
26. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus (HPV) 6, 11, 16, 18 L1 virus-like-particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-9.
27. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-5.
28. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37.
29. Barton SE, Maddox PH, Jenkins D, Edwards R, Cuzick J, Singer A. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988; 2:652-4.
30. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavrus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13:839-46.
31. Poland GA, Gregory A, Jacobson RM, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005; 80:601-10.